Keudell Viking Therapeutics, Inc. Transaction History
Keudell
- $341 Million
- Q2 2024
A detailed history of Keudell transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Keudell holds 4,065 shares of VKTX stock, worth $206,908. This represents 0.06% of its overall portfolio holdings.
Number of Shares
4,065
Previous 3,020
34.6%
Holding current value
$206,908
Previous $247,000
12.96%
% of portfolio
0.06%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
432Shares Held
63.3MCall Options Held
7.39MPut Options Held
5.13M-
Black Rock Inc. New York, NY8.27MShares$421 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.79MShares$396 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.59MShares$183 Million3.55% of portfolio
-
State Street Corp Boston, MA3.33MShares$169 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$118 Million0.02% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.9B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...